Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study
Table 3
Comparison between overweight and obese patients with NAFLD and overweight and obese patients without NAFLD.
Variable
NAFLD patients
Non-NAFLD patients
value
Boys (, %)
12 (46.2%)
23 (54.8%)
0.33
Age (years)
12 (7)
8.50 (5)
0.007
Weight percentile
97.5th (4)
97th (4)
0.22
Waist percentile
95th (4)
95th (7)
0.048
Midarm circumference centile
94th (13)
95th (7)
0.91
BMI (kg/m2)
29.5 (10.70)
24.05 (4.60)
0.004
BMI percentile
98th (2)
98th (2)
0.54
BMI -score
2.10 (0.58)
2.00 (0.75)
0.45
WtHR
61.61 (10.48)
58.6 (5.45)
0.06
Total cholesterol (mg/dL)
163.5 (36)
165 (57)
0.89
LDL cholesterol (mg/dL)
108 (27)
98 (48)
0.63
HDL cholesterol (mg/dL)
35 (18)
45 (17)
0.004
Triglyceride (mg/dL)
127.5 (100)
71 (44)
<0.001
Non-HDL cholesterol (mg/dL)
126.5 (32)
114.5 (48)
0.33
Triglyceride/HDL cholesterol ratio
3.51 (4.15)
1.76 (1.18)
<0.001
C-reactive protein (mg/dL)
0.26 (0.44)
0.46 (1.35)
0.13
Fasting glucose (mg/dL)
89.5 (13)
87 (9)
0.082
ASAT (UI/L)
26 (20)
22 (7)
0.027
ALAT (UI/L)
42.50 (39)
24.5 (11)
<0.001
Alkaline phosphatase (UI/L)
300 (77)
203 (129)
0.084
Uric acid (mg/dL)
5.05 (2.2)
4.40 (2.4)
0.43
Obese (, %)
24 (92.3%)
35 (83.3%)
0.24
Insulin (mU/L)
16.89 (19.45)
7.71 (8.05)
0.015
HOMA-IR
3.69 (3.26)
1.67 (1.93)
0.006
Hypertension (, %)
14 (53.8%)
18 (42.9%)
0.26
Systolic blood pressure centile
90th (45)
50th (41)
0.29
Diastolic blood pressure centile
70th (45)
50th (45)
0.48
Endocan (ng/mL)
2.38 (1.84)
2.69 (2.08)
0.53
Lumican (ng/mL)
12.02 (7.48)
11.97 (5.95)
0.76
Data are presented as median (interquartile range). BMI: body mass index; WtHR: waist to height ratio; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. values were computed with Mann-Whitney tests for continuous variables and Fisher exact test for nominal variables.
